Basket | Login


Bruno Dubois


Bruno Dubois is Professor of Neurology at the Neurological Institute of the University Salpêtrière Hospital in Paris, University Pierre & Marie Curie (UPMC). He is Director of the “Institute for Memory and Alzheimer Disease” (IM2A) , of the Expert Memory Center Paris-Sud and of the Research INSERM Unit on “Cognition and Neuroimaging in Brain Diseases” at the ICM (Institut du Cerveau et de la Moelle Epinière) at the Salpêtrière Hospital.

He is Coordinator of the National Reference Center for “Rare Dementias” (including Fronto-Temporal Dementia, Primary Progressive Aphasia, Progressive Supranuclear Palsy and Cortico-Basal Degeneration) and of the National Reference Multisite Center for “Young-Onset Alzheimer disease”. He is Past President of the Scientific Committee of France-Alzheimer and President of the Scientific Committee of IFRAD (International Fund Raising for Alzheimer’s disease), PSP-France and France-FTD Associations.

He was involved in the elaboration of the Presidential Alzheimer Plan and he is in the Executive Committee of the Plan. He was designed by the French Ministry of Research as the French representative at the European join programming on neurodegenerative diseases. He is a member of the European Alzheimer Disease Consortium (Therapeutics and Intervention Studies).

Prof. Dubois completed his Neurology residency and a fellowship in Behavioral Neurology at the Salpêtrière hospital. His made his PhD on the central cholinergic systems in patients with Parkinson’s disease and in rats. He has published more than 450 peer-reviewed articles on anatomical and biochemical studies on the central cholinergic systems in rodents and humans, on cognitive neuropharmacology, on neuropsychology in patients with dementia, with special reference to memory, executive functions and frontal lobe behaviors and on biomarkers in neurodegenerative disorders. He was co-chairing the task force on the criteria and guidelines for the diagnosis of Parkinson’s disease dementia under the auspices of the Movement Disorders Society. He leads an international working group of experts on the new criteria for Alzheimer Disease. He is principal or co-investigator of a number of research programs focusing on AD, prodromal AD and dementia in Parkinson’s disease.



Last Updated: Friday 06 February 2015